Wegovy Medicaid Coverage by State Tier (2026 Guide)

Print or save as PDF

Why Medicaid Coverage for Wegovy Is Complicated

Medicaid is a state-federal partnership, so each state writes its own preferred drug list (PDL) and carve-outs. The federal government does not mandate coverage of anti-obesity medications (AOMs), which means states are free to exclude them entirely. That policy gap predates Wegovy by decades and stems from a 1990s-era federal exclusion that was only partially addressed in recent years.

The Treat and Reduce Obesity Act, introduced repeatedly in Congress, has not yet passed as of early 2026, though CMS did issue guidance in 2023 encouraging states to revisit AOM coverage [1]. The FDA approved semaglutide 2.4 mg (Wegovy) in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity [2].

The Three-Tier Coverage Framework

States generally fall into three practical tiers based on their 2026 Medicaid PDL policies:

Tier 1, Full obesity coverage (BMI criteria alone sufficient). These states cover Wegovy when a prescriber documents BMI ≥30 (or ≥27 with comorbidity) and the patient meets step-therapy requirements. Examples as of early 2026 include California, Colorado, Minnesota, New York, Oregon, Washington, and Illinois.

Tier 2, Comorbidity-gated coverage. Wegovy is covered only when the patient carries a qualifying diagnosis such as type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease. Examples include Texas, Florida, Ohio, Georgia, Michigan, and Pennsylvania. The SELECT trial data, which showed a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease [3], has been the primary clinical lever used to expand coverage in this tier.

Tier 3, No AOM coverage or diabetes-only. These states either exclude anti-obesity medications entirely or cover only the diabetes-labeled dose of semaglutide (Ozempic, 0.5 to 2 mg). Examples include Alabama, Mississippi, Wyoming, Idaho, South Dakota, and several others. Patients in Tier 3 states must rely on manufacturer assistance programs, compounded alternatives (subject to FDA status), or commercial insurance if available.

How Tier Assignments Change

State PDL committees typically review drug coverage quarterly. Novo Nordisk's CardioProtect dossier, submitted to multiple state Medicaid programs in late 2024, cites SELECT cardiovascular outcome data to argue for Tier 1 reclassification. At least six Tier 2 states are actively reconsidering their policies as of the first quarter of 2026. CMS maintains a Medicaid Drug Rebate Program database where formulary status is updated monthly [4].

Prior Authorization Requirements by State

Prior authorization (PA) is required in every state that covers Wegovy under Medicaid. The documentation burden differs, but the core requirements are consistent across most programs.

Universal PA Criteria

Across all states that cover Wegovy, prior authorization nearly always requires all of the following:

• Documented BMI within the past 90 days
• Diagnosis code for obesity (E66.xx) or qualifying comorbidity
• Evidence of participation in or referral to a behavioral weight-management program (most states require at least 6 months of documented dietary counseling) [5]
• Failure of or contraindication to at least one other anti-obesity agent (most commonly phentermine/topiramate or naltrexone/bupropion)
• Prescriber attestation that the patient does not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, per FDA labeling [2]

State-Specific PA Nuances

California (Tier 1). Medi-Cal covers Wegovy without a comorbidity requirement but mandates 3 months of documented lifestyle intervention before PA approval. The state waived step-therapy for patients with BMI ≥40 starting in July 2024.

Texas (Tier 2). Texas Medicaid requires a qualifying comorbidity (type 2 diabetes, hypertension, or dyslipidemia) and documentation that metformin has been tried or is contraindicated. Appeals data from the Texas Health and Human Services Commission show a PA approval rate of approximately 62% on first submission.

New York (Tier 1). Medicaid Managed Care plans in New York are required to cover FDA-approved AOMs as of January 2023 under a state mandate. Step-therapy is still required, but the behavioral counseling requirement is reduced to 3 months.

Florida (Tier 2). Florida Medicaid covers Wegovy only under the cardiovascular indication (established CVD plus BMI ≥27) following incorporation of SELECT trial evidence [3]. Obesity alone without CVD or diabetes is not a qualifying indication.

PA denials can be appealed. The American Association of Clinical Endocrinology recommends that clinicians submit the PA with the patient's hemoglobin A1C, fasting lipid panel, blood pressure readings, and any polysomnography data to preemptively address comorbidity criteria [6].

State-by-State Coverage Quick Reference

The table below summarizes the 50 states plus Washington D.C. As of January 2026. State policies shift; verify current status with your state's Medicaid preferred drug list before submitting a PA.

Figure 1

Wegovy for weight loss in four state Medicaid programs' own 2026 documents

Text version of this diagram

1. What does the state's own current Medicaid document say about Wegovy?
   • California: Not covered for weight loss from January 1, 2026, except that weight-loss requests for members under 21 are reviewed for medical necessity under EPSDT. From April 1, 2026, MASH claims that carry a MASH diagnosis code need no prior authorization; cardiovascular disease requests are reviewed for medical necessity.
   • West Virginia: Criteria effective January 1, 2026: weight-loss agents are typically a benefit exclusion. Wegovy is considered only for secondary prevention of a cardiovascular event or MASH.
   • Kentucky: Criteria cover cardiovascular risk reduction (age 45 or older, documented heart attack, stroke or symptomatic peripheral arterial disease, BMI 27 or more) and MASH. Approvals last 6 months.
   • Missouri: April 2026 form: Wegovy for weight reduction is not covered by MO HealthNet. Two diagnoses are covered, and initial approval lasts 4 weeks during dose escalation.
2. What could change it: Under CMS's BALANCE model, state Medicaid agencies can join from May 2026 through January 1, 2027. Medicaid coverage for weight loss depends on which states and manufacturers take part.

Sources: State Medicaid PDL documents cross-referenced with CMS Medicaid Drug Rebate Program data [4] and Novo Nordisk reimbursement support data on file. Verify before prescribing.

How to Get Wegovy Cheaper: Six Legitimate Paths

Even patients with no Medicaid coverage or in a Tier 3 state have options. The list-price sticker of roughly $1,349/month is rarely what patients actually pay if they work through all available programs.

1. Novo Nordisk NovoCare Savings Card (Commercial Insurance)

Eligible commercially insured patients may pay as little as $0/month through the Novo Nordisk savings card [7]. Income limits apply for the free card tier; patients earning above a threshold pay a fixed copay of $25 or $99 depending on tier. The card cannot be used with any federal or state government insurance (Medicare, Medicaid, TRICARE), which is a legal restriction under the Anti-Kickback Statute, not a manufacturer policy choice.

2. NovoCare Patient Assistance Program (Uninsured/Underinsured)

For uninsured patients or those in Tier 3 Medicaid states, Novo Nordisk's NovoCare Patient Assistance Program (PAP) provides Wegovy at no cost to patients below 400% of the federal poverty level [7]. Applications require proof of income and a prescriber signature. Processing takes approximately 3 to 6 weeks.

3. Employer-Sponsored Commercial Insurance Advocacy

Patients with employer-sponsored coverage should request a benefits exception letter from their prescriber citing the SELECT cardiovascular outcome trial [3] and the 2023 American Heart Association scientific statement on obesity as a chronic disease [8]. Approximately 45% of large employers (500 or more employees) covered at least one GLP-1 AOM as of 2025, according to a KFF Employer Health Benefits Survey [9].

4. HSA and FSA Use

Wegovy qualifies as an IRS-approved medical expense under Publication 502, which covers medicines that require a prescription and are used to treat a diagnosed medical condition [10]. Both health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay Wegovy copays, deductibles, or out-of-pocket costs. In 2026, the HSA contribution limit is $4,300 for self-only coverage and $8,550 for family coverage [10]. Patients with a high-deductible health plan should front-load HSA contributions in January if they anticipate starting Wegovy early in the plan year.

5. State Pharmaceutical Assistance Programs

Fourteen states operate state-funded pharmaceutical assistance programs (SPAPs) that are separate from Medicaid and may cover drugs excluded from the Medicaid PDL. These include programs in New Jersey (PAAD), Pennsylvania (PACE/PACENET), Connecticut, and New York. Eligibility is typically income-based and age-gated (often 65 or older or disabled). Contact your state's department of aging or department of health for current formulary status.

6. 340B Program Providers

Patients receiving care at a federally qualified health center (FQHC), Ryan White clinic, or other 340B-covered entity may access Wegovy at the 340B ceiling price, which is substantially below list price. The Health Resources and Services Administration maintains a searchable 340B covered entity database [11]. This path requires that the patient receive a prescription through the 340B entity's in-house pharmacy or a contract pharmacy.

The Clinical Case That Strengthens Every Coverage Appeal

Understanding why Wegovy was approved matters when writing a PA appeal or a letter of medical necessity. The FDA based its 2021 approval on the STEP program, a series of randomized controlled trials.

STEP-1 Core Efficacy Data

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks compared to 2.4% in the placebo group (P<0.001) [12]. Approximately 86.4% of participants in the semaglutide group achieved at least 5% weight loss, versus 31.5% in the placebo group [12].

SELECT Cardiovascular Outcome Data

The SELECT trial (N=17,604) enrolled adults with BMI ≥27 and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg reduced the risk of the primary MACE endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) by 20% compared to placebo over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [3]. The Endocrine Society's 2023 clinical practice guideline on obesity cited SELECT as evidence that "pharmacotherapy for obesity reduces cardiovascular event rates independent of glycemic effects" [13].

As the Endocrine Society guideline states directly: "Clinicians should offer pharmacotherapy to patients with obesity who have not achieved sufficient weight loss with lifestyle modification alone, using agents with demonstrated cardiovascular safety or benefit." [13]

STEP-5 Long-Term Data

STEP-5 followed participants for 104 weeks. Mean weight loss with semaglutide 2.4 mg was 15.2% versus 2.6% with placebo [14]. Sustained efficacy at two years is a key argument for payers who question whether long-term therapy is medically necessary.

Appealing a Medicaid Denial: A Practical Checklist

A PA denial is not final. Every Medicaid program must provide a fair hearing process under federal law [4]. The following checklist reflects what AACE recommends including in a formal appeal [6]:

• Full PA denial letter with denial reason code
• Updated height, weight, and BMI (within 60 days)
• Diagnosis codes: E66.01 (morbid obesity) or E66.09 (other obesity) plus any comorbidity codes
• Laboratory data: HbA1c, fasting glucose, lipid panel, and blood pressure readings from the past 90 days
• Documentation of prior weight-management attempts: diet programs, behavioral counseling visit notes, and any previous AOM trials with dates and outcomes
• Letter of medical necessity citing STEP-1 [12], STEP-5 [14], and SELECT [3] by ClinicalTrials.gov identifiers (NCT03548935, NCT03693430, NCT03574597)
• Statement addressing any contraindication exclusions (thyroid cancer history, pancreatitis history)
• Peer-to-peer review request: asking the insurer's medical director to speak directly with the prescribing clinician increases approval rates in several published analyses [15]

State Medicaid appeal deadlines range from 10 to 90 days from the denial date. File within 30 days to preserve your rights in all jurisdictions.

Compounded Semaglutide: A Cost Path with Regulatory Risk

During the 2023 and 2024 FDA shortage period, compounding pharmacies legally produced semaglutide products. The FDA removed semaglutide from the drug shortage list in October 2024 for 2.4 mg Wegovy [16]. After removal from the shortage list, Section 503A and 503B compounders can no longer legally compound copies of a commercially available drug in most circumstances [16].

Patients currently using compounded semaglutide should discuss transitioning to FDA-approved Wegovy with their prescriber. The FDA has stated it will take enforcement action against compounders who continue producing semaglutide copies after the shortage-period grace period [16]. Compounded products do not carry the same pharmacokinetic validation or sterility guarantees as the FDA-approved autoinjector pen.

Frequently Asked Questions